USA flag logo/image

An Official Website of the United States Government

Portable Gas Perfusion System for Pancreas Preservation

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
Giner, Inc.
89 Rumford Avenue Newton, MA 02466-1311
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 2
Fiscal Year: 2010
Title: Portable Gas Perfusion System for Pancreas Preservation
Agency: HHS
Contract: 2R44DK070400-03A1
Award Amount: $1,610,843.00


DESCRIPTION (provided by applicant): Portable Gas Perfusion System for Pancreas Preservation. A Phase II SBIR program is proposed to further develop the novel pancreas preservation technique and system for future implementation with human pancreata for cli nical islet transplantation. Methods to enhance preservation of pancreata with resulting improvements in islet yield and quality, and ultimately in clinical outcome, are urgently needed to move the field of islet transplantation forward for the treatment o f type 1 diabetes. Arterial persufflation of the pancreas during storage to provide oxygen throughout the organ at the capillary level was shown in Phase I to be feasible, promising and superior to the current state-of-the-art. Persufflation is a term for perfusing an organ with a gas stream to provide oxygen. In Phase I, pancreata were preserved for up to 24 hours and had superior quality (by histology, microscopy and quantitative islet quality measurements) to those stored with the standard two layer meth od. This SBIR Phase II program plans to concurrently provide the advanced engineering equipment and the advanced research demonstrations of the effectiveness of pancreatic persufflation as a superior organ preservation technique. The project combines the e xpertise of Giner, Inc., an engineering RandD firm, and the University of Minnesota Schulze Diabetes Institute, a leading pancreatic islet transplantation center. The Specific Aims of the Phase II program are to: 1) fabricate persufflator prototypes; 2) de velop an integrated, portable persufflation system: the Pancreas Preservation System; 3) demonstrate that persufflation during cold preservation can extend pancreas preservation time; 4) demonstrate that persufflation after standard cold preservation can i mprove islet quality; 5) fabricate 10 integrated, portable persufflation systems; and 6) demonstrate Pancreas Preservation System with shipments. The Ph II work now includes persufflation of human pancreata, as very promising preliminary work with human or gans was performed in Ph I. Inclusion of human pancreata testing in Ph II research effort brings persufflation preservation closer to the final clinical application in human islet allotransplantation. Porcine pancreata are also used in some tasks, as they remain an excellent model and their procurement can be scheduled; there is also a long term clinical application in human islet xenotranplantation. The oxygen persufflation system will be reliable, easy-to-use, transportable, and will provide a complete, p atented system for standardized use in the islet transplantation community. The overall project goal is to provide commercial equipment for pancreas storage and shipment with a new persufflation preservation protocol. Furthermore, the oxygen persufflation system can be readily adapted for use in preservation and transport of other organs, including the liver, kidney and heart. Customers for this product will include transplantation centers, islet isolation centers, and Organ Procurement Organizations. PUBLIC HEALTH RELEVANCE: The proposed Phase II SBIR project continues to develop technology for improved preservation of donor pancreata by oxygenation. Pancreatic islets are isolated from donor pancreata and used in allogenic islet transplantation, an e xperimental procedure for treating severe cases of Type-I diabetes. Improved pancreas preservation (increased storage time, increased islet yield and quality) is important to the clinical outcome of islet transplantation.

Principal Investigator:

Linda A. Tempelman

Business Contact:

Anthony B. Laconti
Small Business Information at Submission:


EIN/Tax ID: 104252980
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No